Skip to content
value.today
Seres Therapeutics, Inc. logo

Seres Therapeutics, Inc.

MCRB
$20 Mmarket cap on Oct 30, 2026-89.0% since Jan 2024
Compare
World rank
#24,364
Revenue
$1 M
For year ending December-2025
Net income
$6 M
721.5% margin
SEC filing
Employees
333
As on 2021
value.today research

Seres Therapeutics, Inc. in brief

Seres Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Cambridge, Massachusetts, USA. It was founded in 2010. Its market value was $20 M on 30 October 2026, which makes it the 24,364th largest listed company in the world and the 4,161st largest in the USA on this site. In the year to December 2025 it had sales of $1 M and a net profit of $6 M. It employs about 333 people and Eric Shaff is its chief executive. Its shares trade under the symbol MCRB (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Seres Therapeutics, Inc.

Seres Therapeutics is a Late Clinical Stage Biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome. The company annual revenue is 35 million USD and 145 employees as on 2020. The headquarters is in USA.

Seres Therapeutics, Inc. timeline

5 events, 2010–2021
  1. 2010
  2. 🏁
    · approximate
    Founded
  3. 2014
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2015
  6. ✎
    Renamed Seres Therapeutics, Inc.
    Formerly Seres Health, Inc..
  7. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 26 June 2015; shares registered for exchange trading on 22 June 2015.
  8. 2021
  9. 💰
    Record revenue of $145 million
    FY2021, the highest of the 6 years on record.

Events of Seres Therapeutics, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$604 M$1.2 B$1.8 B$2.4 B2020202120222023202420252026

World rank over time

▼ down 9,144 places since 2020
2020-01-01: #15246#15,24620202021-01-01: #5120#5,12020212022-01-07: #10779#10,77920222022-12-25: #10764#10,76420222023-07-30: #11583#11,58320232024-01-05: #18438#18,43820242026-03-08: #10249#10,24920262026-08-01: #19737#19,73720262026-10-30: #24390#24,3902026

Rank in USA: #3,131 (Jan 2020) · #1,573 (Jan 2021) · #2,780 (Jan 2022) · #2,367 (Dec 2022) · #2,526 (Jul 2023) · #3,326 (Jan 2024) · #1,995 (Mar 2026) · #3,767 (Aug 2026) · #4,164 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
3.5×
Price / sales
25.2×
Price / book
0.4×
Free cash flow yield
4.4%
Net margin
721.5%
Operating margin
-11894.9%
Return on equity
12.9%
Liabilities / assets
68.0%
Net debt
$-18M
Revenue growth
-88.9%
R&D / revenue
6210.1%
Revenue per employee
$2 K
Profit per employee
$17 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $28M, net income $-99M$28MFY18Fiscal year ending Dec 2019: revenue $35M, net income $-70M$35MFY19Fiscal year ending Dec 2020: revenue $33M, net income $-89M$33MFY20Fiscal year ending Dec 2021: revenue $145M, net income $-66M$145MFY21Fiscal year ending Dec 2022: revenue $7M, net income $-250M$7MFY22Fiscal year ending Dec 2023: revenue —, net income $-114M—FY23Fiscal year ending Dec 2024: revenue —, net income $0M—FY24Fiscal year ending Dec 2025: revenue $1M, net income $6M$1MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$1M—$-94M$6M721.5%
Dec 2024——$-121M$0M—
Dec 2023——$-195M$-114M—
Dec 2022$7M-95.1%$-180M$-250M-3508.6%
Dec 2021$145M+336.3%$-64M$-66M-45.2%
Dec 2020$33M-3.7%$-88M$-89M-268.3%
Dec 2019$35M+22.0%$-72M$-70M-203.7%
Dec 2018$28M—$-100M$-99M-350.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$1M$0M$1M$0.64—
Dec 2024$-149M$0M$-149M$0.00—
Dec 2023$-117M$8M$-125M$-17.77—
Dec 2022$-229M$10M$-239M$-2.31—
Dec 2021$7M$10M$-3M$-0.72—
Dec 2020$-94M$1M$-94M$-1.12—
Dec 2019$-77M$1M$-78M$-1.24—
Dec 2018$-63M$2M$-65M$-2.43—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-16M—Dec ’24Three months to Mar 2025: revenue —, net income $33M—Mar ’25Three months to Jun 2025: revenue —, net income $-20M—Jun ’25Three months to Sep 2025: revenue $0M, net income $8M$0MSep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-15M—Dec ’25Three months to Mar 2026: revenue $0M, net income $-20M$0MMar ’26Three months to Jun 2026: revenue $1M, net income $5M$1MJun ’26Three months to Sep 2026: revenue $1M, net income $-16M$1MSep ’26

Latest quarter to Sep 2026: revenue $1M (+68.6% on a year earlier), net income $-16M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Seres Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$1 M
Operating income
$-94 M
Net income
$6 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$138 M
Total liabilities
$94 M
Total equity
$44 M

As of December-2025

Top 40 institutional investors in Seres Therapeutics, Inc.#

As of Sep 30, 2026
40 institutions held 2.3 M shares (about 23.0% of the shares outstanding) on Sep 30, 2026. The ten largest hold 21.2%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Seres Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Flagship Pioneering, LLC1,155,8500 (0.00%)11.34%$4 MNov 16, 2026
2Vanguard Capital Management LLC286,405-1,371 (-0.48%)2.81%$1 MNov 13, 2026
3Marshall Wace, LLP139,278-32,967 (-19.14%)1.37%$0 MNov 13, 2026
4Jacobs Levy Equity Management, Inc134,375New1.32%$0 MNov 16, 2026
5Vontobel Holding Ltd.114,566-8,409 (-6.84%)1.12%$0 MOct 16, 2026
6BlackRock, Inc.109,827-1,173 (-1.06%)1.08%$0 MNov 13, 2026
7Geode Capital Management, LLC78,898-1,076 (-1.35%)0.77%$0 MNov 6, 2026
8Susquehanna International Group, LLP62,692+4,364 (+7.48%)0.61%$0 MNov 16, 2026
9Vanguard Fiduciary Trust Co48,6850 (0.00%)0.48%$0 MNov 13, 2026
10State Street Corp33,9010 (0.00%)0.33%$0 MNov 12, 2026
11Lion Point Capital, LP31,5700 (0.00%)0.31%$0 MNov 16, 2026
12Goldman Sachs Group Inc17,888+2,659 (+17.46%)0.18%$0 MNov 16, 2026
13Quadrature Capital Ltd17,428New0.17%$0 MNov 13, 2026
14J. Safra Sarasin Holding AG14,997New0.15%$0 MOct 26, 2026
15Northern Trust Corp14,750-15 (-0.10%)0.14%$0 MNov 16, 2026
16Invesco Ltd.12,603-371 (-2.86%)0.12%$0 MNov 12, 2026
17Morgan Stanley12,283+145 (+1.19%)0.12%$0 MNov 13, 2026
18Renaissance Technologies LLC11,791New0.12%$0 MNov 12, 2026
19Squarepoint Ops LLC11,523New0.11%$0 MNov 9, 2026
20XTX Topco Ltd10,705-10,027 (-48.36%)0.10%$0 MNov 16, 2026
21Group One Trading LLC3,7140 (0.00%)0.04%$0 MNov 10, 2026
22SBI Securities Co., Ltd.3,601-581 (-13.89%)0.04%$0 MOct 22, 2026
23UBS Group AG3,493+3,009 (+621.69%)0.03%$0 MNov 10, 2026
24Tower Research Capital LLC (TRC)2,173+1,857 (+587.66%)0.02%$0 MNov 16, 2026
25Vanguard Global Advisers, LLC1,9750 (0.00%)0.02%$0 MNov 13, 2026
Show all 40: investors 26 to 40
Institutional investors 26 to 40 in Seres Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Nuveen, LLC1,773New0.02%$0 MNov 10, 2026
27FMR LLC1,730+202 (+13.22%)0.02%$0 MNov 10, 2026
28Rachor Investment Advisory Services, LLC1,185-292 (-19.77%)0.01%$0 MOct 29, 2026
29Jpmorgan Chase & Co746-2,890 (-79.48%)0.01%$0 MNov 12, 2026
30Royal Bank Of Canada316+305 (+2772.73%)0.00%$0 MNov 16, 2026
31Pinnacle Financial Group, Inc.300—0.00%$0 MNov 16, 2026
32BNP Paribas Financial Markets214+3 (+1.42%)0.00%$0 MNov 12, 2026
33Continuum Advisory, LLC470 (0.00%)0.00%$0 MNov 13, 2026
34PNC Financial Services Group, Inc.23New0.00%$0 MNov 6, 2026
35Simplex Trading, LLC18-4,580 (-99.61%)0.00%$0 MNov 4, 2026
36Wells Fargo & Company/mn100 (0.00%)0.00%$0 MNov 16, 2026
37Osaic Holdings, Inc.80 (0.00%)0.00%$0 MNov 12, 2026
38Larson Financial Group LLC50 (0.00%)0.00%$0 MNov 5, 2026
39Barclays PLC4-163 (-97.60%)0.00%$0 MNov 6, 2026
40Allworth Financial LP4New0.00%$0 MNov 17, 2026

Mutual funds holding Seres Therapeutics, Inc.#

22 funds hold shares worth $4 M (about 4.8% of the company). Since their previous reports 8 added shares and 11 sold, selling $0 M net.
Mutual funds holding Seres Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.206,170$2 M2.0%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.75,849$1 M0.74%<0.01%+8.4%Jun 30, 2026
🇺🇸 Avantis U.S. Small Cap Value ETFAmerican Century ETF Trust37,364$0 M0.37%<0.01%−33%May 31, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.31,077$0 M0.30%<0.01%−1.4%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors25,389$0 M0.25%0.01%+52%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC26,335$0 M0.26%<0.01%+8.9%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC13,870$0 M0.14%<0.01%no changeMay 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.10,065$0 M0.10%<0.01%+277%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC10,143$0 M0.10%<0.01%no changeMay 31, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC12,914$0 M0.13%<0.01%−11%Jul 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC7,500$0 M0.07%0.04%no changeJun 30, 2026
🇺🇸 WisdomTree U.S. SmallCap FundWisdomTree Asset Management, Inc.7,058$0 M0.07%<0.01%−2.3%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC5,666$0 M0.06%<0.01%+26%May 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust5,277$0 M0.05%<0.01%−2.9%May 31, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP7,662$0 M0.08%<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.4,386$0 M0.04%<0.01%+25%Jun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC1,689$0 M0.02%<0.01%+28%Jun 30, 2026
🇺🇸 Large-Cap Growth PortfolioPacific Life Fund Advisors LLC1,430$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.1,371$0 M0.01%<0.01%−91%Jun 30, 2026
🇺🇸 Avantis U.S. Small Cap Value FundAmerican Century ETF Trust1,176$0 M0.01%<0.01%no changeMay 31, 2026
🇺🇸 Avantis U.S. Equity ETFAmerican Century ETF Trust1,022$0 M0.01%<0.01%no changeMay 31, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC42$0 M<0.01%<0.01%+17%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 22 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Seres Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$11 K
16 sales, 5 insiders
Net, 12 months
-$11 K
open market only
Insiders on file
25
since
-$45 K$0Feb 2024: bought $0 (0 trades), sold $35 K (7 trades)Feb 24May 2024: bought $0 (0 trades), sold $6 K (6 trades)Aug 2024: bought $0 (0 trades), sold $32 K (7 trades)AugOct 2024: bought $0 (0 trades), sold $17 K (5 trades)Nov 2024: bought $0 (0 trades), sold $3 K (5 trades)NovFeb 2025: bought $0 (0 trades), sold $23 K (5 trades)May 2025: bought $0 (0 trades), sold $3 K (4 trades)MayAug 2025: bought $0 (0 trades), sold $7 K (4 trades)Nov 2025: bought $0 (0 trades), sold $45 K (4 trades)NovFeb 2026: bought $0 (0 trades), sold $4 K (4 trades)May 2026: bought $0 (0 trades), sold $4 K (4 trades)MayAug 2026: bought $0 (0 trades), sold $2 K (4 trades)Nov 2026: bought $0 (0 trades), sold $795 (4 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
Seres Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Matthew R. HennSee RemarksSell10b5-1 plan-101$1.380$1398,132Form 4
filed Eric D. ShaffDirectorSell10b5-1 plan-287$1.380$39612,936Form 4
filed Thomas DesRosierSee RemarksSell10b5-1 plan-103$1.380$1428,258Form 4
filed Kelly BradySee RemarksSell10b5-1 plan-85$1.380$1178,775Form 4
filed Matthew R. HennSee RemarksOption exercise10b5-1 plan+238——8,233Form 4
filed Eric D. ShaffDirectorOption exercise10b5-1 plan+724——13,223Form 4
filed Thomas DesRosierSee RemarksOption exercise10b5-1 plan+244——8,361Form 4
filed Kelly BradySee RemarksOption exercise10b5-1 plan+181——8,860Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Seres Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
342,237
3.6% of shares · 4.31 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 20-for-1 split

Trading halts

  • 2026-02-12 11:55 UTC, code T3, resumed 12:30 UTC
  • 2025-04-23 13:34 UTC, code LUDP, resumed 13:47 UTC
  • 2025-04-21 23:50 UTC, code T3, resumed 13:00 UTC

Fails to deliver

  • : 10,229 shares at $1.95
  • : 10,000 shares at $1.79
  • : 4,704 shares at $1.80
  • : 1,460 shares at $2.31
  • : 71 shares at $2.42

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Seres Therapeutics, Inc. scorecard#

Passes 8 of the 14 checks that could be worked out: strongest in profitability (2 of 3), weakest in financial health (1 of 3). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation3 of 5
    • ✓P/E below its peers' median3.5×P/E 3.5× against Biotechnology's median of 17.5×.
    • ✓Price to book below its peers' median0.5×Price to book 0.5× against Biotechnology's median of 2.9×.
    • ✗Price to sales below its peers' median25.2×Price to sales 25.2× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%4.4%Free cash flow is 4.4% of the market value.
    • ✓Earnings yield above the 10-year Treasury yield28.7%Earnings yield 28.7% against the 10-year Treasury's 5.15% on 2026-11-13.
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth2 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✓Earnings per share grew in the newest year0.64 vs 0.00Diluted EPS 0.64 in fiscal 2025 against 0.00 the year before (report's currency).
    • ✓Net income higher than five years earlier$6 M$6 M in fiscal 2025 against -$89 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability2 of 3
    • ✓Profitable in the newest year$6 MNet income $6 M in fiscal 2025.
    • ✗Profitable in each of the last five years2 of 5Profitable in 2 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✓Return on equity above 15%19.7%19.7% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities2.6×Current ratio 2.56 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-11.70Z-score -11.70 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year14.2%Diluted shares up 14.2% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Seres Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Seres Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue0.800r7.11453335283222
Research and development4965118r110r1429180968982
General and administrative395378r70r693125333433
Operating expenses95121195r180r209121106129123115
Operating income−94−121−195r−180r−64−88−72−100−91−93
Interest and finance income2.24.07.33.12.90.91.01.21.6—
Interest expense and finance costs002.5r6.02.92.90.5———
Net interest income————————1.61.3
Other non-operating income (expense)100−4.55.0r−3.7−1.1−1.01.61.32.01.3
Income tax0000000000
Income from continuing operations5.7−126−190−184——————
Income from discontinued operations012676−67——————
Net income attributable to shareholders5.70.1−114−250−66−89−70−99−89−92
Earnings per share, basic0.640.00-17.77r-2.31-0.72-1.12-1.24-2.43-2.21-2.30
Earnings per share, diluted0.640.00-17.77r-2.31-0.72-1.12-1.24-2.43-2.21-2.30
Shares, weighted average (basic)8.97.8r6.4r1089280————
Shares, weighted average (diluted)8.97.8r6.4r108928057414040
Balance sheet
Cash and cash equivalents463112816318011665863655
Short-term investments——018111138300114139
Receivables0.20———9.41.8———
Inventory——300——————
Other current assets3.15.88.0r13135.83.66.85.15.1
Current assets493917519530426910093155198
Property, plant and equipment7.61218r23181419263336
Right-of-use (leased) assets728190r111189.011———
Long-term investments———00.550———37
Total assets138140359349355343132120190273
Accounts payable1.74.13.617144.04.96.47.07.6
Current liabilities19419986824646423230
Lease liabilities (non-current)738392r108181116———
Total liabilities94126403338223168181169129140
Retained earnings−972−978−978−865−614−549−460−389−264−174
Shareholders' equity4414−4511132175−48−4861133
Total liabilities and equity138140359349355343132120190273
Shares outstanding9.6r8.7r135125929170414140
Cash-flow statement
Depreciation and amortization4.15.56.26.65.96.67.67.97.34.2
Share-based compensation11213425208.88.3171717
Cash from operating activities1.1−149−117−2296.7−94−77−63−7644
Capital expenditure−0.3−0.4−8.0−9.8−9.6−0.6−1.0−1.9−4.7−21
Cash from investing activities−0.0142118264−159−3111256r−66r
Debt issued00103280025———
Shares issued—0097024461———
Shares bought back————————−0.0—
Cash from financing activities14−90721301.2303860.30.12.1
Change in cash—————51−2150−20r−20r
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Seres Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.8 M
Eric Shaff, Thomas DesRosier, Marella Thorell
Other top executives, average
$1.0 M
the CEO earned 1.7× this
$100 invested is now
$13
Seres Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Eric Shaff, Thomas DesRosier, Marella Thorell$1.8 M$1.4 M$1.0 M$13
2024Eric Shaff$2.7 M$1.9 M$1.3 M$15
2023Eric Shaff$3.2 M−$518 K$1.7 M$25

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Seres Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Acquisition or sale completed 1 · Directors and officers 8 · Material agreement 3 · Agreement ended 2 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 10

Seres Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Results announced8-K
Material agreementAgreement ended8-K
Directors and officersShareholder vote8-K
Material agreement8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Bylaws or fiscal year changed8-K
Directors and officersShareholder vote8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Delisting noticeResults announced8-K
Acquisition or sale completedMaterial agreementAgreement endedUnregistered share sale8-K
Shareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 4, 2026

Acquisitions and funding#

3 private funding rounds before listing

Private share sales · funding history

Private share sales of Seres Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2014$65 MNo. 3$50 to $250 million1equitySEC
Nov 2014$48 MNo. 2$10 to $50 million20equitySEC
May 2014$11 MNo. 1$10 to $50 million10equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Seres Therapeutics, Inc.#

2 labor condition applications certified in fiscal 2026 for 2 positions, at a median wage of $117 K a year.

Certified, FY2026
2
#1,528 among companies on value.today
Worker positions
2
Median wage offered
$117 K
a year, full-time
Applications filed
2
Seres Therapeutics, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Senior Associate, ManufacturingBiochemists and Biophysicists1$106 K
Senior Scientist, Analytical DevelopmentBiochemists and Biophysicists1$127 K

Where: Cambridge, MA 2

Seres Therapeutics, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202622$117 K2
FY202544$108 K4
FY202377$104 K7
FY20221212$119 K12
FY202155$100 K5
FY202011$115 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Seres Therapeutics, Inc.

How Seres Therapeutics, Inc. compares in Biotechnology

  • Market cap$20 M · higher than 17% of 726
  • Revenue$1 M · higher than 23% of 647
  • P/E ratio3.5× · lower than 90% of 100
  • Price / sales25.2× · lower than 27% of 339
  • Price / book0.5× · lower than 93% of 534
  • FCF yield4.4% · higher than 94% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Seres Therapeutics, Inc.🇺🇸$20 M3.5×——
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on 2021
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Seres Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Seres Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Seres Therapeutics, Inc.? Suggest a correction